Page 59 - Read Online

REFERENCES 24. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E,
Haferlach T. Acute myeloid leukemia with mutated nucleophosmin
(NPM1): is it a distinct entity? Blood 2011;117:1109-20.
1. Schiller GJ. Evolving treatment strategies in patients with high-risk 25. Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer
acute myeloid leukemia. Leuk Lymphoma 2014;55:2438-48.
2. Meyer SC, Levine RL. Translational implications of somatic genomics A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M,
Ehninger G, Brown D, Illmer T. miR-10a overexpression is associated
in acute myeloid leukaemia. Lancet Oncol 2014;15:e382-94.
3. Arceci RJ, Berman JN, Meshinchi S. Acute myeloid leukemia. In: with NPM1 mutations and MDM4 downregulation in intermediate-
risk acute myeloid leukemia. Exp Hematol 2011;39:1030-42.e7.
Arceci GD, editor. Cancer Genomics. Boston: Academic Press; 2014. 26. Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J,
p. 283-300. Neumann A, Pouryamout L. Prognostic significance of FLT3 internal
4. Tabe Y, Konopleva M. Advances in understanding the leukaemia tandem duplication, nucleophosmin 1, and CEBPA gene mutations
microenvironment. Br J Haematol 2014;164:767-78. for acute myeloid leukemia patients with normal karyotype and
5. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic younger than 60 years: a systematic review and meta-analysis. Ann
stem cells. Nature 2014;505:327-34. Hematol 2014;93:1279-86.
6. Stölzel F, Röllig C, Radke J, Mohr B, Platzbecker U, Bornhäuser M, 27. Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan
Paulus T, Ehninger G, Zöphel K, Schaich M. 18 F-FDG-PET/CT for RH, Borowitz MJ, Berg KD, Murphy KM. FLT3 mutations in myeloid
detection of extramedullary acute myeloid leukemia. Haematologica sarcoma. Br J Haematol 2004;126:785-91.
2011;96:1552-6. 28. Colovic N, Tomin D, Vidovic A, Tosic N, Atkinson HD, Colovic MD.
7. Yilmaz AF, Saydam G, Sahin F, Baran Y. Granulocytic sarcoma: a Central nervous system relapse in CD56+, FLT3/ITD+promyelocytic
systematic review. Am J Blood Res 2013;3:265-70. leukemia. Med Oncol 2012;29:260-2.
8. Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression 29. Muroi K, Fujiwara S, Tatara R, Sugimoto M, Yamamoto C, Uehara
of amyloid precursor protein in acute myeloid leukemia enhances E, Meguro A, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T,
extramedullary infiltration by MMP-2. Tumor Biol 2013;34:629-36. Mori M, Nagai T, Ozawa K. CD56 expression in normal immature
9. Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and granulocytes after allogeneic hematopoietic stem cell transplantation.
therapeutic options. Ther Adv Hematol 2011;2:309-16. J Clin Exp Hematopathol 2013;53:247-50.
10. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary 30. Yang LL, Gan SL, Liu YF, Zhang QT, Li T, Ma J, Sun H. Clinical
acute myeloid leukemia. Blood 2011;118:3785-93. characteristics of CD56(+) patients with acute monocytic leukemia
11. Tirado CA, Chen W, Valdez F, Karandikar N, Arbini A, Acevedo and their prognostic significance. Zhongguo Shi Yan Xue Ye Xue Za
I, Garcia R, Davila O, Smart RL, Matthews E, Kirk A, Collins Zhi 2013;21:596-600.
RH. Unusual presentation of myeloid sarcoma in a case of acute 31. Breccia M, De Propris MS, Minotti C, Stefanizzi C, Raponi S,
promyelocytic leukemia with a cryptic PML-RARA rearrangement Colafigli G, Latagliata R, Guarini A, Foà R. Aberrant phenotypic
involving multiple sites including the atrium. Cancer Genet Cytogenet expression of CD15 and CD56 identifies poor prognostic acute
2010;200:47-53. promyelocytic leukemia patients. Leuk Res 2014;38:194-7.
12. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, 32. Mitteldorf C, Bertsch HP, Baumgart M, Haase D, Wulf G, Schön MP,
Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor? Int J Rosenwald A, Neumann C, Kaune KM. Lacking CD56 expression in
Cancer 2013;133:534-43. a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm
13. Ganzel C, Douer D. Extramedullary disease in APL: a real phenomenon after allogeneic bone marrow transplantation: FISH analysis revealed
to contend with or not? Best Pract Res Clin Haematol 2014;27:63-8. loss of 11q. J Eur Acad Dermatol Venereol 2011;25:1225-9.
14. Zhang XH, Zhang R, Li Y. Granulocytic sarcoma of abdomen in acute 33. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M.
myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: Extramedullary relapse of AML with t(9;11) (p22;q23) associated
case report and review of literature. Leuk Res 2010;34:958-61. with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med
15. Shvartsbeyn M, Meehan SM, Gu P, Nierodzik ML, Perle MA. 2010;49:447-51.
Trisomy 8 in myeloid leukemia cutis confirmed by fluorescence in situ 34. Tamaki H, Yoshihara S, Fujioka T, Kawakami M, Oka Y, Ogawa H.
hybridization analysis. J Cutan Pathol 2012;39:1026-9. Molecular detection of AML1-MTG8-positive cells in peripheral
16. Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top blood from a patient with isolated extramedullary relapse of t(8;21)
Microbiol Immunol 2007;313:85-100. acute myeloid leukemia. Leukemia 2009;23:424-6.
17. Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, Chen S, Li Y. Inhibition of 35. Lan TY, Lin DT, Tien HF, Yang RS, Chen CY, Wu K. Prognostic
long non-coding RNA NEAT1 impairs myeloid differentiation in acute factors of treatment outcomes in patients with granulocytic sarcoma.
promyelocytic leukemia cells. BMC cancer 2014;14:693. Acta Haematol 2009;122:238-46.
18. Naina HV, Levitt D, Vusirikala M, Anderson LD Jr, Scaglioni PP, 36. Calvi LM, Link DC. Cellular complexity of the bone marrow
Kirk A, Collins RH Jr. Successful treatment of relapsed and refractory hematopoietic stem cell niche. Calcif Tissue Int 2014;94:112-24.
extramedullary acute promyelocytic leukemia with tamibarotene. J 37. Saki N, Abroun S, Farshdousti Hagh M, Asgharei F. Neoplastic bone
Clin Oncol 2011;29:e534-6. marrow niche: hematopoietic and mesenchymal stem cells. Cell J
19. De Braekeleer E, Meyer C, Douet-Guilbert N, Basinko A, Le Bris 2011;13:131-6.
MJ, Morel F, Berthou C, Marschalek R, Férec C, De Braekeleer M. 38. Fukuda S, Onishi C, Pelus LM. Trafficking of acute leukemia
Identification of MLL partner genes in 27 patients with acute leukemia cells-chemokine receptor pathways that modulate leukemia cell
from a single cytogenetic laboratory. Mol Oncol 2011;5:555-63. dissemination. In: Antica M, editor. Acute Leukemia: The Scientist’s
20. Wu B, Li F, Zou S. MLL-AF9 rearrangement in myeloid sarcomas Perspective and Challenge. Rijeka: InTech; 2011.
involving the breast. Ann Hematol 2014;93:709-10. 39. Faaij CM, Willemze AJ, Révész T, Balzarolo M, Tensen CP,
21. Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B. Hoogeboom M, Vermeer MH, van Wering E, Zwaan CM, Kaspers
Extramedullary infiltrates of AML are associated with CD56 GJ, Story C, an Halteren AG, Vossen JM, Egeler RM, an Tol
expression, 11q23 abnormalities and inferior clinical outcome. Leuk MJ, Annels NE. Chemokine/chemokine receptor interactions
Res 2004;28:1007-11. in extramedullary leukaemia of the skin in childhood AML:
22. Gallo A, Lo Sterzo C, Mori M, Di Matteo A, Bertini I, Banci L, Brunori differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr
M, Federici L. Structure of nucleophosmin DNA-binding domain Blood Cancer 2010;55:344-8.
and analysis of its complex with a G-quadruplex sequence from the 40. Wang C, Chen Z, Li Z, Cen J. The essential roles of matrix
c-MYC promoter. J Biol Chem 2012;287:26539-48. metalloproteinase-2, membrane type 1 metalloproteinase and tissue
23. Chen HY, Lu QY. Research on NPM1 gene mutations in acute myeloid inhibitor of metalloproteinase-2 in the invasive capacity of acute
leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013;21:258-62. monocytic leukemia SHI-1 cells. Leuk Res 2010;34:1083-90.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦ 49